Nb-redirected CAR T cells potently eradicate AML tumor in vivo. (A-B) Ten million THP-1 cells were transplanted into NSG mice subcutaneously. The tumor reached 150 mm³ after ∼14 days. Three million Nb157 T cells, Nb163 CAR T cells, or UTD T cells were injected IV into the mice separately (n = 4). Tumor engraftment was monitored every other day. Scale bar, 10 mm. (C) Hematoxylin and eosin–stained THP-1 xenografts after treatment with UTD T cells, Nb163 CAR T cells, or Nb157 CAR T cells. Scale bars, 100 μm. (D) Three million Nb157 CAR T cells or UTD T cells were injected IV separately into NSG mice bearing HL60 tumors. Tumor engraftment was monitored every other day (n = 4). (E) Five million K562 cells were transplanted into NSG mice subcutaneously. The tumor reached 150 mm³ after ∼10 days. Three million Nb157 CAR T cells, Nb163 CAR T cells, or UTD T cells were injected into NSG mice separately. Tumor engraftment was monitored every other day (n = 4). (F) A total of 1.5 million Nb157 CAR T cells, Nb163 CAR T cells, or UTD T cells was injected IV separately into NSG mice bearing THP-1 tumor. Tumor engraftment was monitored every other day until the tumors were gone completely (n = 4). ***P < .001, 1-way analysis of variant. ns, not significant.